Validation of Airway Epithelial Cell TP53 Biomarker for Lung Cancer Risk

Abstract

Conclusion: These results support the validity of the TP53 mutation prevalence biomarker and justify taking additional steps to assess this biomarker in AEC specimens from a prospective cohort and in matched nasal brushing specimens as a potential non-invasive surrogate specimen.